Free Trial
NASDAQ:APLT

Applied Therapeutics (APLT) Stock Price, News & Analysis

$4.24
+0.04 (+0.95%)
(As of 04:00 PM ET)
Today's Range
$4.07
$4.32
50-Day Range
$4.19
$6.90
52-Week Range
$1.18
$9.39
Volume
570,835 shs
Average Volume
1.68 million shs
Market Capitalization
$484.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Applied Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
165.1% Upside
$11.00 Price Target
Short Interest
Healthy
3.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.99mentions of Applied Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$2.47 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.56 out of 5 stars

Medical Sector

88th out of 921 stocks

Pharmaceutical Preparations Industry

29th out of 419 stocks

APLT stock logo

About Applied Therapeutics Stock (NASDAQ:APLT)

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

APLT Stock Price History

APLT Stock News Headlines

Applied Therapeutics Rallies After Announcing Private Placement Of Shares
See More Headlines
Receive APLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
5/21/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:APLT
Fax
N/A
Employees
25
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$13.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+161.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-119,760,000.00
Pretax Margin
-1,198.47%

Debt

Sales & Book Value

Annual Sales
$9.99 million
Book Value
($0.20) per share

Miscellaneous

Free Float
104,440,000
Market Cap
$479.93 million
Optionable
Optionable
Beta
1.91

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Shoshana Shendelman Ph.D. (Age 45)
    Chair of the Board of Directors, Founder, President, CEO & Secretary
    Comp: $813.47k
  • Mr. Les D. Funtleyder (Age 53)
    CFO, Principal Financial Officer & Independent Director
    Comp: $40k
  • Dr. Riccardo Perfetti M.D. (Age 63)
    Ph.D., Chief Medical Officer
    Comp: $858k
  • Mr. Adam Hansard (Age 47)
    Chief Commercial Officer
    Comp: $742.66k
  • Mr. Constantine Chinoporos (Age 58)
    COO & Chief Business Officer
  • Ms. Catherine Thorpe (Age 60)
    Chief Accounting Officer

APLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Applied Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APLT shares.
View APLT analyst ratings
or view top-rated stocks.

What is Applied Therapeutics' stock price target for 2024?

5 analysts have issued 1-year target prices for Applied Therapeutics' stock. Their APLT share price targets range from $7.00 to $13.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 165.1% from the stock's current price.
View analysts price targets for APLT
or view top-rated stocks among Wall Street analysts.

How have APLT shares performed in 2024?

Applied Therapeutics' stock was trading at $3.35 on January 1st, 2024. Since then, APLT shares have increased by 23.9% and is now trading at $4.15.
View the best growth stocks for 2024 here
.

When is Applied Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our APLT earnings forecast
.

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics, Inc. (NASDAQ:APLT) released its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.18. The company earned ($0.67) million during the quarter.

What ETF holds Applied Therapeutics' stock?

Simplify Propel Opportunities ETF holds 2,817,505 shares of APLT stock, representing 12.14% of its portfolio.

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS) and RTX (RTX).

When did Applied Therapeutics IPO?

Applied Therapeutics (APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.

Who are Applied Therapeutics' major shareholders?

Applied Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (5.61%), Propel Bio Management LLC (5.35%), Knoll Capital Management LLC (4.88%), Vanguard Group Inc. (2.64%), StemPoint Capital LP (1.77%) and Artal Group S.A. (0.88%). Insiders that own company stock include Charles Silberstein, Chids Mahadevan, Leslie D Funtleyder, Real Estate Equitie Alexandria, Riccardo Perfetti, Shoshana Shendelman and Stacy J Kanter.
View institutional ownership trends
.

How do I buy shares of Applied Therapeutics?

Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APLT) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners